BioMotiv Secures $21 Million in Initial Funding
CLEVELAND – September 5, 2012
BioMotiv today announced that it has secured $21 million in financing from its founding investors, University Hospitals and the Harrington Family.
BioMotiv is a new model for accelerating breakthrough discoveries into medicines and aligning capital
and collaborations to develop a portfolio of therapeutics,â€ said Baiju R. Shah, Chief Executive Officer of BioMotiv. “Through their commitment, University Hospitals and the Harrington family have once
again demonstrated their dedication to solving a major national challenge that prevents promising
discoveries from advancing to patient benefit.”